Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

American Association for Cancer Research

April 25 - 30, 2025

Trastuzumab Deruxtecan
Datopotamab Deruxtecan
Durvalumab
Osimertinib
Savolitinib

pdf

An open-label, multicenter, Phase 2 study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors: DESTINY-PanTumor02

pdf

Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) treatment for HER2-positive (HER2+) metastatic colorectal cancer (mCRC) in DESTINY-CRC02 (DC-02)

ppt

Trastuzumab Deruxtecan-Siena S, et al. Biomarker analysis DC-02 [Poster supplement].

pdf

Resistance to trastuzumab deruxtecan (T-DXd) in breast cancer via loss of HER2 expression and binding

pdf

Trastuzumab deruxtecan induces immunogenic cell death, immune cell activation and migration in viable human breast cancer slices

pdf

The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 Normalized Membrane Ratio

pdf

Intrinsic payload resistance governs responses to datopotamab deruxtecan, a TROP2 antibody drug conjugate, in pancreatic cancer model systems

pdf

Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC

ppt

Longitudinal circulating tumor DNA (ctDNA) analysis and acquired mechanisms of resistance to osimertinib (osi) in the China cohort of the FLAURA study

pdf

SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi

pdf

A phase I open-label positron-emission tomography study to determine brain exposure of [11C] savolitinib in healthy volunteers

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização